This educational program consists of three presentations on benefits of SLGT2 inhibitors in heart failure.

This course consists of the following:

• The clinical challenges of initiating guideline recommended therapy in HF - Prof. John McMurray, MD - Glasgow, UK
• Benefits and evolving insights on SGLT2i in the spectrum of LVEF - Prof. Carolyn Lam, MD, PhD - Singapore
• Expanding evidence on SGLT2i: Where are we now and what can we expect? - Prof. Scott Solomon, MD - Boston, MA, USA

How to obtain your CME certificate

• Watch the three lectures and answer the pre- and post-test questions
• Fill in the evaluation questions
• Download CME Certificate (if your score >70%)

After watching these three videos, the learner should be able to:

• Identify barriers of implementing findings from clinical trials and recommendations in guidelines for treatment of HFrEF
• Interpret findings from CV outcomes trials with SGLT2i in HF patients
• Describe details of ongoing trials with SGLT2i in HF patients across the entire spectrum of LVEF

Expert faculty

• Prof. John McMurray, MD - Glasgow, UK
• Prof. Carolyn Lam, MD, PhD - Singapore
• Prof. Scott Solomon, MD - Boston, MA, USA

Target audience

This educational activity is designed for all healthcare professionals with an interest in management of patients with heart failure.

CME accreditation

This online course is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit.

Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

Funding

Funding for this educational program was provided by an unrestricted educational grant from AstraZeneca.

Questions

For questions regarding this activity, please contact us at info@pace-cme.org.